A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma Non-small-cell Lung
- Colorectal Neoplasms
- Neoplasms
- Pancreatic Neoplasms
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03948763
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director, MD Merck Sharp & Dohme Corp.